Is (KZR) Outperforming Other Medical Stocks This Year?

This pandemic has affected us all, and we wanted to share Kezar’s response during this time of crisis and provide a brief update on our research and development activities and overall business operations. The health and safety of our employees and of those involved in our clinical trials is paramount. Over the last few weeks, we have been in close communication with the investigators and site staff participating in our three clinical trials with KZR-616.

They imply a low investment risk, as their balance sheets are moderately leveraged Continue reading...

Kezar Life Sciences (KZR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced its first quarter 2020 financial results and corporate highlights. “During this unprecedented health crisis, I’ve been deeply impressed by our team’s focus and continued execution across both of our programs,” said John Fowler, Kezar’s Chief Executive Officer.

SOUTH SAN FRANCISCO, Calif., May 20, 2020 -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule.

In the span of eight days last month, CytomX Therapeutics Inc. landed a collaboration with Astellas Pharma and captured a $40 million milestone payment from AbbVie Inc. as it preps for a mid-stage cancer clinical trial. “It’s a challenging time for our industry,” said CytomX President and CEO Sean McCarthy.

SOUTH SAN FRANCISCO, Calif., Nov. 27, 2019 -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule.

We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmune disease and cancer, today announced the pricing of an underwritten public offering of 16,115,385 shares of its common stock, and to certain investors in lieu thereof, pre-funded warrants to purchase 2,884,615 shares of its common stock at an exercise price of $0.001 per share. The public offering price of each share of common stock is $2.60 and the public offering price of each pre-funded warrant is $2.599. In addition, Kezar has granted the underwriters a 30-day option to purchase additional shares of common stock of up to 15% of the aggregate number of shares of common stock plus the shares of common stock underlying the pre-funded warrants being offered in the offering.

SOUTH SAN FRANCISCO, Calif., Feb. 26, 2020 -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule.

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmune disease and cancer, today announced the closing of an underwritten public offering of 16,115,385 shares of its common stock, and to certain investors in lieu thereof, pre-funded warrants to purchase 2,884,615 shares of its common stock at an exercise price of $0.001 per share. The public offering price of each share of common stock was $2.60 and the public offering price of each pre-funded warrant was $2.599.

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmune disease and cancer, highlighted work from its research and development platform focusing on Sec61 translocon inhibition during the 61st American Society of Hematology (ASH) Annual Meeting and Exposition taking place in Orlando, FL from December 7-10, 2019. Two oral presentations and one poster presentation focus on novel inhibitors of the Sec61 translocon, which demonstrate high degrees of potency against a large number of therapeutically relevant oncology and immuno-oncology targets that are Sec61 client proteins, translating into broad anti-tumor activity.

Phase 2 MARINA, MISSION and PRESIDIO trials with KZR-616 are progressingAdditional data from the ongoing Phase 1b portion of the MISSION study to be presented during various.

Investors who take an interest in Kezar Life Sciences, Inc. (NASDAQ:KZR) should definitely note that the Independent...

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Kezar Life Sciences (NASDAQ:KZR) Inc on Monday, setting a price target of $9, which is approximately 49.75% above the present share price of $6.01.

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced the appointment of Noreen R. Henig, MD as its Chief Medical Officer. As an integral member of the Company’s Executive Leadership team, Dr. Henig will oversee all aspects of the Company’s clinical development, regulatory and medical affairs. “Noreen brings with her a depth and breadth of expertise in clinical practice, translational science, clinical development, and medical affairs, and we are thrilled to welcome her to the Kezar team,” said John Fowler, Kezar’s Chief Executive Officer.

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmune disease and cancer, today announced the appointment of Elizabeth Garner, MD, MPH to its Board of Directors. Dr. Garner is currently the Chief Medical Officer of ObsEva SA. “Beth’s addition to the board brings a wealth of clinical development, regulatory, and medical affairs experience,” said Jean-Pierre Sommadossi, PhD, Chairman of the Board at Kezar.

Top Ranked Momentum Stocks to Buy for May 11th